REMEVi Health Launches Bilingual Telehealth Platform Built to Close the Language Gap in U.S. Healthcare

REMEVi Health, a bilingual telehealth platform, today launched nationwide, providing GLP-1 weight-loss care and provider-prescribed peptide and injectable therapies to English- and Spanish-speaking patients across the United States. Built to operate fully in both languages from the ground up, REMEVi delivers every step of care — from the medical intake form to provider consultations to medication instructions — in English and Spanish, addressing a long-standing gap in U.S. telehealth for the country's largest non-English-speaking population.

A gap in U.S. healthcare

The United States is home to more than 62 million Hispanic and Latino residents, and roughly 42 million people speak Spanish at home — the largest non-English language group in the country, according to the U.S. Census Bureau. Yet most major telehealth platforms were built in English and, at best, partially translated into Spanish afterward. The consequences are well documented: studies of U.S. hospitals have found that patients with limited English proficiency experience adverse events more often than English-proficient patients, and that those events are more likely to result in physical harm. Language barriers in healthcare are not an inconvenience — they are a measurable patient-safety problem.

Built by founders who lived the problem

REMEVi Health was co-founded by Blake Chapman and Danai Del Carmen Chapman, a husband-and-wife team who experienced the gap firsthand. Danai, a native Spanish speaker, went through her own weight-management treatment as a patient and found that the medication itself was rarely the hardest part — making sense of appointments, instructions, and decisions about her own body in a second language was.

"I was making decisions about my own health while still translating English in my head," said Danai Del Carmen Chapman, co-founder of REMEVi. "Medicine should not require translation. We built REMEVi so that no patient has to choose between getting care and fully understanding it."

Bilingual at every touchpoint

Unlike platforms that rely on automatic translation, REMEVi Health was designed bilingual at every touchpoint. Its intake system, patient portal, clinical summaries, medication instructions, and care-coordinator support were all built in English and Spanish at the same time. Every patient case is reviewed by a board-certified, state-licensed provider — a physician (MD) or nurse practitioner — and bilingual care coordinators respond to patients within a two-hour window.

Care delivered in both languages

REMEVi Health offers two areas of care — GLP-1 weight-loss programs and provider-prescribed peptide and injectable therapies — each delivered fully in English and Spanish, from the first intake question through ongoing follow-up. Any prescription is issued only after an individual medical evaluation by a licensed provider, and only when that provider determines it is clinically appropriate for the patient. Where a program involves compounded medication, those preparations are made by state-licensed pharmacies for the individual patient. Full program details and transparent pricing are published on the company's website.

Compliance built in

REMEVi Health is certified by LegitScript — the verification standard for online healthcare recognized by Google, Microsoft, and Meta — and operates on HIPAA-compliant infrastructure. The company does not use artificial intelligence to make prescribing decisions; every prescription is issued by a licensed clinician after an individual medical review.

"We built REMEVi bilingual from the first line of code — Spanish is not a translation layer, it is how the platform was designed," said Blake Chapman, co-founder of REMEVi Health. "We also decided early that compliance would not be an afterthought. We completed LegitScript certification before opening to patients, because trust has to be earned before the first appointment, not after."

Availability

REMEVi Health is available now to patients in all 50 states and Washington, D.C. Patients can check their eligibility through a free bilingual assessment at remevihealth.com.

About REMEVi Health

REMEVi Health is a bilingual telehealth platform providing GLP-1 weight-loss care and provider-prescribed peptide and injectable therapies to English- and Spanish-speaking patients across the United States. Founded in 2026 and headquartered in Las Vegas, Nevada, REMEVi Health was built to deliver every step of care equally in English and Spanish, pairing board-certified, state-licensed providers (physicians and nurse practitioners) with bilingual care coordinators. REMEVi Health is LegitScript-certified and HIPAA-compliant. The company's tagline — "Your Health. Your Terms." / "Tu Salud. Tus Reglas." — reflects its focus on patient empowerment and accessible, culturally competent care. Learn more at remevihealth.com.

Disclaimer

REMEVi Health connects patients with licensed healthcare providers and is not a pharmacy or a drug manufacturer. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA) and are not reviewed by the FDA for safety, effectiveness, or quality. Prescription treatments are available only if a licensed provider determines they are appropriate following a medical evaluation; not all patients will be eligible. Individual results vary, and no specific health outcome is guaranteed. This press release is for informational purposes only and does not constitute medical advice. Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. REMEVi is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.

Media Contact

Blake Chapman
Founder, REMEVi Health
press@remevihealth.com
+1 702-352-4746